Keisuke Kinoshita

Keisuke Kinoshita

Auto-generated profile, based on publicly available information

Keisuke Kinoshita

Department of Gastroenterology Faculty of Medicine Oita University Oita Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Laboratory Investigation
Verified
Journal Article
Open access
KKKeisuke Kinoshita
Keisuke Kinoshita
YTYoshiyuki Tsukamoto
Yoshiyuki Tsukamoto
YHYuka Hirashita
Yuka Hirashita
TFTakafumi Fuchino
Takafumi Fuchino
SKShusaku Kurogi
Shusaku Kurogi
NHNaoki Hijiya
Naoki Hijiya
Patient-derived tumor organoids have considerable potential as an in vitro diagnostic tool for drug susceptibility testing. In the present study, we investigated whether bile collected for diagnostic purposes could be a potential source for the establishment of biliary cancer organoids. Among 68 cases of biliary cancer, we successfully generated 60 bile-derived organoids (BDOs) from individual patients. Consistent with previous reports that described biliary cancer organoids from surgical tissues, the BDOs showed diverse morphologies such as simple cysts, multiloculated cysts, thick capsulated cysts, and solid masses. They also harbored mutations in KRAS and TP53 at frequencies of 15% and 55%, respectively. To enrich the cancer organoids by removing contaminated noncancerous components of BDOs, we attempted to verify the effectiveness of 3 different procedures, including repeat passage, xenografting, and selection with an MDM2 inhibitor for TP53 mutation-harboring BDOs. By monitoring the sequence and expression of mutated TP53, we found that all these procedures successfully enriched the cancer organoids. Our data suggest that BDOs can be established with minimal invasiveness from almost all patients with biliary cancers, including inoperable cases. Thus, despite some limitations with respect to the characterization of BDOs and methods for the enrichment of cancer cell-derived organoids, our data suggest that BDOs have potential applications in personalized medicine.

15 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YTYoshiyuki Tsukamoto
Yoshiyuki Tsukamoto
YHYuka Hirashita
Yuka Hirashita
TSTomotaka Shibata
Tomotaka Shibata
SFShoichi Fumoto
Shoichi Fumoto
SKShusaku Kurogi
Shusaku Kurogi
NHNaoki Hijiya
Naoki Hijiya
Prediction of therapeutic outcomes is important for cancer patients in order to reduce side effects and improve the efficacy of anti-cancer drugs. Currently, the most widely accepted method for predicting the efficacy of anti-cancer drugs is gene panel testing based on next-generation sequencing. However, gene panel testing has several limitations. For example, only 10% of cancer patients are estimated to have druggable mutations, even if whole-exome sequencing is applied. Additionally, even if optimal drugs are selected, a significant proportion of patients derive no benefit from the indicated drug treatment. Furthermore, most of the anti-cancer drugs selected by gene panel testing are molecularly targeted drugs, and the efficacies of cytotoxic drugs remain difficult to predict. Apart from gene panel testing, attempts to predict chemotherapeutic efficacy using ex vivo cultures from cancer patients have been increasing. Several groups have retrospectively demonstrated correlations between ex vivo drug sensitivity and clinical outcome. For ex vivo culture, surgically resected tumor tissue is the most abundant source. However, patients with recurrent or metastatic tumors do not usually undergo surgery, and chemotherapy may be the only option for those with inoperable tumors. Therefore, predictive methods using small amounts of cancer tissue from diagnostic materials such as endoscopic, fine-needle aspirates, needle cores and liquid biopsies are needed. To achieve this, various types of ex vivo culture and endpoint assays using effective surrogate biomarkers of drug sensitivity have recently been developed. Here, we review the variety of ex vivo cultures and endpoint assays currently available.

3 March 2020 in Clinical Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
KKKeisuke Kinoshita
Keisuke Kinoshita
OMOsamu Matsunari
Osamu Matsunari
ASAkira Sonoda
Akira Sonoda
KFKensuke Fukuda
Kensuke Fukuda
KOKazuhisa Okamoto
Kazuhisa Okamoto
KMKazunari Murakami
Kazunari Murakami
Gastrointestinal Dieulafoy’s ulcer is a rare disease of unknown etiology. Dieulafoy’s ulcer often presents in the stomach and is thought to cause about 5% of all gastrointestinal bleeds in adults, but can be found in any part of the gastrointestinal tract. Dieulafoy’s ulcer corresponds to an arterial malformation in the submucosal space and can cause life-threatening hemorrhage. We report a case of the lower gastrointestinal bleeding from a cecal Dieulafoy’s ulcer that was successfully treated with endoscopic clips. An 82-year-old woman had been diagnosed with hypertension and cerebral infarction. She had been using aspirin to prevent recurrent infarction. She was admitted to our hospital with hematochezia. Urgent colonoscopy revealed a small, reddish vascular malformation in the cecum. The lesion was suggestive of Dieulafoy’s ulcer and was treated with endoscopic clips. The patient has since been discharged from our hospital without experiencing any further bleeding. Endoscopy is a useful method for diagnosing and treating Dieulafoy’s ulcer.

25 March 2021 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
KKKeisuke Kinoshita
Keisuke Kinoshita
SFSatoshi Fukuchi
Satoshi Fukuchi
KFKensuke Fukuda
Kensuke Fukuda
KOKazuhisa Okamoto
Kazuhisa Okamoto
RORyo Ogawa
Ryo Ogawa
KMKazunari Murakami
Kazunari Murakami

20 December 2022 in DEN Open
Verified
Journal Article
Open access
KKKeisuke Kinoshita
Keisuke Kinoshita
KMKazuhiro Mizukami
Kazuhiro Mizukami
KFKensuke Fukuda
Kensuke Fukuda
KOKazuhisa Okamoto
Kazuhisa Okamoto
RORyo Ogawa
Ryo Ogawa
KMKazunari Murakami
Kazunari Murakami
A 74‐year‐old man was diagnosed with unresectable pancreatic cancer with obstructive jaundice. Chemotherapy with gemcitabine and nab‐paclitaxel was initiated after placement of a duckbill‐shaped anti‐reflux metal stent (D‐ARMS). A period of 1 month after D‐ARMS placement, the patient developed hematemesis and entered severe shock following emergency admission for further evaluation.Contrast‐enhanced computed tomography revealed a pseudoaneurysm in the gastroduodenal artery, coincident with the site of D‐ARMS placement, and bleeding from the same site was diagnosed. Angiography was performed, and the pseudoaneurysm was successfully treated by transcatheter arterial embolization using coils. The patient was subsequently discharged from hospital and experienced no further bleeding until his death due to an aggravation of the pancreatic cancer after 2 months. We report a case of pancreatic cancer with pseudoaneurysm after D‐ARMS placement.

22 November 2025 in DEN Open
Verified
Journal Article
Open access
KKKeisuke Kinoshita
Keisuke Kinoshita
KOKazuhisa Okamoto
Kazuhisa Okamoto
HNHaruna Noguchi
Haruna Noguchi
SFSatoshi Fukuchi
Satoshi Fukuchi
HAHidetoshi Akiyama
Hidetoshi Akiyama
KMKazunari Murakami
Kazunari Murakami
Objectives: Pancreatic fluid collections (PFCs) are able to develop secondary to either fluid leakage or liquefaction of acute pancreatitis, chronic pancreatitis, pancreatic trauma, or after pancreatic surgery. While most PFCs resolve spontaneously, endoscopic procedures are sometimes necessary. Endoscopic ultrasound‐guided transluminal drainage (EUS‐TD) using lumen‐apposing metal stents (LAMS) is now widely performed for PFCs. This study investigated the incidence of complications and points to be considered during and after EUS‐TD using LAMS for the treatment of patients with PFCs. Methods: This three‐center retrospective study investigated patients who underwent EUS‐TD using LAMS or using a double‐pigtail plastic stent (DPS) for the treatment of PFCs at the University of Oita Hospital and affiliated institutions from December 2018 to June 2024. The primary outcome was the clinical success rate. Secondary outcomes included the technical success rate, endoscopic procedure time, LAMS indwell term, adverse events (AEs), and post‐LAMS placement course. Results: Twenty‐five patients (mean age, 67.5 ± 15.4 years; 76% male) underwent LAMS placement for PFCs. Median size of PFCs was 90 mm (range, 40–227 mm). A clinical success rate was achieved in 96%. The technical success rate was 96%, and the median endoscopic procedure time was 11 min (range, 5–32 min). Median LAMS indwell term was 46 days (range, 36‐60 days). AEs were bleeding and stent migration. Post‐LAMS placement course was good in 22 patients. No patients required re‐treatment after LAMS removal. Conclusions: EUS‐TD using LAMS is a simple procedure for the treatment of PFCs and appears clinically effective, highly safe, and efficient compared to conventional EUS‐TD using DPS.